Principal Financial Group Inc. Acquires 10,827 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Principal Financial Group Inc. raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 841,011 shares of the biopharmaceutical company's stock after purchasing an additional 10,827 shares during the quarter. Principal Financial Group Inc. owned 0.53% of TG Therapeutics worth $33,161,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Arizona State Retirement System boosted its holdings in shares of TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after purchasing an additional 364 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 433 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after acquiring an additional 463 shares during the last quarter. NBC Securities Inc. lifted its stake in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 823 shares during the last quarter. Finally, Redwood Investments LLC lifted its stake in shares of TG Therapeutics by 0.9% in the 4th quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company's stock valued at $2,846,000 after acquiring an additional 886 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price target for the company in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $43.80.

TG Therapeutics Price Performance

Shares of TGTX traded down $0.59 during trading hours on Friday, reaching $37.08. The stock had a trading volume of 957,478 shares, compared to its average volume of 2,877,974. The stock has a market capitalization of $5.89 billion, a PE ratio of 154.50 and a beta of 1.91. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. TG Therapeutics, Inc. has a 12 month low of $16.65 and a 12 month high of $46.48. The company's 50-day moving average is $36.05 and its two-hundred day moving average is $35.28.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The firm's revenue for the quarter was up 90.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.07) earnings per share. Research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Transactions at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director directly owned 228,816 shares of the company's stock, valued at $8,452,463.04. This trade represents a 4.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.